ArticleTherapeutic advances in ophthalmology
COVID-19 and conjunctivitis: a meta-analysis.
Article in Therapeutic advances in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Ophthalmic complications associated with COVID-19: a large US national database analysis.Eye (London, England) · 2025Article
- Ocular Lesions Related to COVID-19 and Its Vaccines.Journal of ophthalmology · 2025Review
- Ocular manifestations of COVID-19: A systematic review of current evidence.Preventive medicine reports · 2024Review
- Antiseptics: An expeditious third force in the prevention and management of coronavirus diseases.Current research in microbial sciences · 2024Review
- Vitamin A Deficiency, COVID-19, and Rhino-Orbital Mucormycosis (Black Fungus): An Analytical Perspective.Advances in experimental medicine and biology · 2023Article
- Coronavirus Disease 2019-Related Health Disparities in Ophthalmology with a Retrospective Analysis at a Large Academic Public Hospital.Advances in ophthalmology and optometry · 2022Review
- Conjunctival epithelial cells resist productive SARS-CoV-2 infection.Stem cell reports · 2022Article
- Acute and sub-acute ocular manifestations in pediatric patients with COVID-19: A systematic review.Medical hypothesis, discovery & innovation ophthalmology journal · 2022Review
- I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections.Frontiers in immunology · 2022Review
- COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) · 2021Review
- Ocular manifestations of COVID-19.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a disease first identified in Wuhan City, Hubei Province, China, in December 2019, causes by a SARS-COV-2 virus infection. By 27 October 2020, 43,921,473 confirmed cases were reported worldwide, with 1,166,389 COVID-19 deaths. Conjunctivitis has been reported in adults and pediatric patients with COVID-19.
objectiveThe aim of this meta-analysis is to estimate the odd Ratio (ORs) of conjunctivitis in patients with COVID-19.
methodsA systematic review and meta-analysis have been performed using the PubMed and Google Scholar literature search. The ORs of conjunctivitis in adults and pediatric patients is the outcome of this meta-analysis.
resultsThere have been 1041 articles published since the outbreak in December 2019, according to the latest literature. For the meta-analysis, 20 studies with a total of 3383 participants were included. The odds ratio (ORs) of conjunctivitis was 0.01 (95% confidence interval [CI]: 0.00-0.02). No bias has been reported.
conclusionConjunctivitis is the most common ocular manifestations reported in adults. This comprehensive meta-analysis quantifies the existing evidence linking conjunctivitis with COVID-19 and highlights the high percentage of heterogeneity that is shown in the current studies. Finally, it offers a single review article which includes all the current articles available for COVID-19 and conjunctivitis in adults and children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.